Breast Cancer
Conditions
Keywords
HR+/HER2-,, advanced breast cancer,, ribociclib,, non-steroidal aromatase inhibitors,, first-line treatment
Brief summary
Observational, longitudinal (retrospective cohort), multicenter, national study aiming to evaluate the proportion of women with HR+/HER2- advanced breast cancer treated with ribociclib plus non-steroidal aromatase inhibitors who were alive and without disease progression at 1 year.
Detailed description
The study was conducted in 11 Brazilian sites specialized in the treatment of this condition. The study data were collected from the review of medical records by the Investigator (or designated). The sites must have had adequate medical records to ensure robust medical record review. Therefore, a feasibility assessment was carried out at potential site prior to the study implementation to assess the adequacy of medical records and the data routinely available.
Interventions
DRUGRibociclib
Included patients who received doses (600 mg, 400 mg, and 200 mg) at 6 months and 1 year
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Female patient ≥ 18 years of age. All the patients must have at least one year of follow-up * Patients at an age not consistent with postmenopausal status could only participate if they had oophorectomy surgery or being on treatment with goserelin for ovarian suppression Post-menopausal women defined as age ≥ 60 years old or \< 60 years old and amenorrhea for 12 months or more (in the absence of chemotherapy, tamoxifen, toremifene or goserelin use for ovarian suppression) * Confirmed diagnosis of HR+/HER2- locally advanced or metastatic BC * Never in use of CDK 4/6i
Exclusion criteria
* Patients in menopause status other than postmenopausal (young patients must have undergone oophorectomy being on treatment with goserelin for ovarian suppression to be characterized as postmenopausal) * Previous use, at any time, of CDK 4/6i * The patient received any previous systemic therapy for advanced breast cancer Patients who have received (neo)adjuvant therapy for breast cancer are eligible. If previous (neo) adjuvant therapy has included letrozole or anastrozole, the disease- free interval should be longer than 12 months from completion of treatment until entry in this trial Patients who received ≤28 days of letrozole or anastrozole for advanced disease prior to inclusion in this trial are eligible * Uncontrolled heart disease and/or clinically significant cardiac repolarization abnormalities
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients alive and progression-free from disease at 1 year | 1 year post-treatment | The purpose was to evaluate the effectiveness of first-line ribociclib in combination with non-steroidal aromatase inhibitors in a Brazilian female population diagnosed with HR+/HER2- locally advanced or metastatic BC. Effectiveness was measured by the proportion of patients alive and free of disease progression at 1 year. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who had disease progression at 6 months | 6 months post-treatment | The purpose was to evaluate the proportion of patients who had disease progression at 6 months. |
| Proportion of patients who had disease progression at 1 year | 1 year post-treatment | The purpose was to evaluate the proportion of patients who had disease progression at 1 year. |
| Proportion of patients who died at 6 months | 6 months post-treatment | The purpose was to evaluate the proportion of patients who died at 6 months. |
| Proportion of patients who died at 1 year | 1 year post-treatment | The purpose was to evaluate the proportion of patients who died at 1 year. |
| Proportion and cause of patients who reduced a treatment dose at 6 months | 6 months post-treatment | Patients who reduced a treatment dose (from 600 mg to 400 mg or from 400 mg to 200 mg) |
| Proportion of patients alive and progression-free from disease at 6 months | 6 months post-treatment | The purpose was to evaluate the effectiveness of first-line ribociclib in combination with non-steroidal aromatase inhibitors in a Brazilian female population diagnosed with HR+/HER2- locally advanced or metastatic BC. Effectiveness was measured by the proportion of patients alive and free of disease progression at 6 months post-treatment. |
| Frequency of dose interruption and cause, per patient, at 1 year | 1 year post-treatment | The purpose was to evaluate frequency of dose interruption and cause, per patient, at 1 year. |
| Adverse Event frequency and classification of the severity degree | throughout the study, approximately 1 year | Frequency and classification of the degree of severity of the following adverse events of interest: neutropenia, febrile neutropenia, increased QT interval (\> 60 ms,\> 480ms ≤ 500 ms, and\> 500 ms), AST/ALT elevation three times greater than upper limit. In relation to the adverse events of interest, they were classified regarding the severity, graded from 1 to 4, corresponding to mild, moderate, severe and life-threatening, or as described in the medical record. |
| Pattern of the treatment of AE of interest at 6 months | 6 months post-treatment | Pattern of the treatment of AE of interest were reported to evaluate how the patients with AE of interest were treated. |
| Pattern of the treatment of AE of interest at 12 months | 12 months post-treatment | Pattern of the treatment of AE of interest were reported to evaluate how the patients with AE of interest were treated. |
| Proportion and cause of patients who reduced a treatment dose at 1 year | 1 year post-treatment | Patients who reduced a treatment dose (from 600 mg to 400 mg or from 400 mg to 200 mg) |
Countries
Brazil
Outcome results
None listed